Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696470 | 1.00 | PTGS2 (0.38) | PTGS2ARPDE4BPTGS1TYK2 | |
| SCHEMBL22143156 | 0.88 | MAPT (0.42) | PTGS2ARPTGS1TYK2S1PR1 | |
| SCHEMBL25791902 | 0.88 | PTGS2 (0.43) | PTGS2PDE4BPTGS1USP1 | |
| SCHEMBL30696341 | 0.88 | KLKB1 (0.40) | PTGS2PDE4BPTGS1USP1 | |
| SCHEMBL27174332 | 0.88 | KLKB1 (0.40) | PTGS2PDE4BPTGS1USP1 | |
| SCHEMBL27174318 | 0.88 | USP1 (0.40) | PTGS2PDE4BPTGS1USP1 | |
| SCHEMBL30816570 | 0.83 | POLB (0.42) | POLB | |
| SCHEMBL27174298 | 0.83 | POLB (0.42) | POLB | |
| SCHEMBL22122093 | 0.82 | PTGS2 (0.52) | PTGS2PTGS1USP1POLB | |
| SCHEMBL27174409 | 0.81 | KDM4E (0.40) | PTGS2PDE4BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | PTGS2 3472/4885AR 3688/4885PDE4B 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.